Fig 1: NNK upregulated CD36 expression and sarcolemmal distribution were required for NNK-induced lung cell carcinogenesis(A) Detection of CD36 and α7nAChR expression in lung cells. Bet1A, NCI-H23, and A549 cells were untreated or treated with 10 μM NNK for 12 h. Proteins expression was examined as indicated. Non-NNK treatment cell was set as control. The relative intensity of protein bands was summarized by column figure and expressed as mean ± SD (n = 3, ∗p < 0.05 and ∗∗p < 0.01 vs. Control).(B) CD36 distribution after NNK stimulation. Bet1A and NCI-H23 cells were untreated or treated with NNK for 0.5 and 12 h, respectively. Cells without NNK treatment were the control. Cells were double stained for CD36 (red) and ATPase (green), respectively. Bar, 10 μm. The images were representative of three experiments.(C) NNK treatment promoted lung cell viability. Cells treated with 10 μM NNK for different time were used for MTT assay (∗∗p < 0.01, n = 5).(D and E) NNK induced Bet1A and NCI-H23 cell migration (D) and invasion (E). Cells treated by NNK for 24 h were used for cell migration and invasion assay. Images were taken using phase contrast microscope (Nikon) (scale bar, 200 μm). The numbers of migration or invasion cells in eight randomly selected fields were counted and the average number of cells in one field was calculated and expressed as the mean ± SD (∗∗p < 0.01 vs. Control).(F) CD36 regulated Akt activation in NNK-treated lung cells. Scramble and ShCD36 cells of Bet1A and NCI-H23 were untreated or treated with NNK as indicated. The levels of CD36 and Akt activity were examined with indicated antibodies.(G) CD36 was required for maintaining cell viability. Scramble and ShCD36 cells of Bet1A and NCI-H23 were treated with NNK as indicated for MTT assay (∗p < 0.05 and ∗∗p < 0.01 vs. scramble control; #p < 0.05 and ##p < 0.01 vs. scramble+NNK, n = 6).(H and I) CD36 was required for NNK-induced cell migration (H) and invasion (I). Scramble and ShCD36 cells of Bet1A and NCI-H23 treated with NNK for 24 h were detected by trans-well experiment for cell migration and invasion, respectively. Images were taken using phase contrast microscope (Nikon) (scale bar, 200 μm). The numbers of migration or invasion cells in eight randomly selected fields were counted and the average number of cells in one field was calculated and expressed as the mean ± SD (∗p < 0.05 and ∗∗p < 0.01 vs. scramble control; #p < 0.05 and ##p < 0.01 vs. scramble+NNK).
Fig 2: CD36-/- A/J mice counteracted NNK-induced LUAD tumor formation(A) Construction of CD36+/− A/J background mice. CD36+/− C57BL/6 mice were backcrossed to A/J mice for five generations to generate CD36+/− A/J background mice. The homozygosity of A/J background mice by back-crossed five generations was 96.87%.(B) F5 A/J mice genotyping by PCR. No. 4–9 mice obtained a 226 bp band as CD36+/+ wild type. No. 1, 3, 14, 16, 18, and 20 mice obtained both 226 and 318 bp bands as CD36+/− genotype. No. 2, 10, 11, 12, 13, 15, 17, 19, 21, and 22 mice obtained a 318 bp band as CD36−/− genotype.(C) CD36-/- A/J mice counteracted NNK-induced LUAD tumor formation. The WT (CD36+/+) and KO (CD36−/−) A/J mice were injected intraperitoneally (ip) with either NNK (100 mg/kg) or equivalent volume of physiological saline. Mice were humanely culled 16 weeks later and the lung nodules were calculated. (∗∗p < 0.01 vs. WT; ##p < 0.01 vs. WT NNK; @@p < 0.01 vs. KO).(D) Pathologic analyses of the lungs in A/J mice. Lung tissue sections from WT (CD36+/+), KO (CD36−/−), WT (CD36+/+)-NNK, and KO (CD36−/−)-NNK A/J mice group were stained with H&E and examined. Bar: 600 and 200 μm, respectively.(E) IHC staining of the lungs in A/J mice. Lung tissue sections from WT (CD36+/+), KO (CD36−/−), WT (CD36+/+)-NNK, or KO (CD36−/−)-NNK A/J mice group were stained with CD36 antibody and examined. Bar: 200 and 50 μm, respectively.
Fig 3: NNK activated Akt/ERK1/2 via α7nAChR-CD36-Src pathway(A and B) NNK activated Src/Akt/ERK1/2 through α7nAChR (A) and Effect of CD36 knockdown was similar as α7nAChR inhibitors (B).The constructed cells as indicated in the figures were untreated or treated with 10 μM NNK, or cells were pretreated with 1 μM α7nAChR receptor inhibitor benzethonium chloride (BZN) or 10 μM α7nAChR receptor inhibitor methylacetonitine citrate (MLA) for 30 min, which was followed by 10 μM NNK treatment for another 0.5 or 12 h, respectively. Untreated cells were set up as controls. Proteins expression and activity were determined by western blot.(C and D) NNK activated Akt/ERK1/2 through Src kinase (C) and Effect of CD36 knockdown was similar as Src inhibitors (D).The constructed cells as indicated in the figures were untreated or treated with 10 μM NNK, or cells were pretreated with 10 μM Src kinase family inhibitor SU6656 or 100 nM Src kinase inhibitor dasatinib for 30 min, which was followed by 10 μM NNK treatment for 0.5 or 12 h, respectively. Untreated cells were set up as controls. Proteins expression and activity were determined by western blot.
Fig 4: Downregulation of CD36 expression inhibited NNK-induced LUAD tumor growth and metastasis in xenograft mouse models(A) CD36 knockdown in LUAD cells inhibited xenograft tumor growth. The nude mice were subcutaneously transplanted with A549-scramble, A549-scramble-NNK, A549-ShCD36, or A549-ShCD36-NNK cells, respectively. The tumor was collected 6 weeks later and the size of tumor was measured (n = 10, ∗p < 0.05 and ∗∗p < 0.01 vs. Scramble; ##p < 0.01 vs. ShCD36; @@p < 0.01 vs. Scramble-NNK).(B) CD36 knockdown in LUAD cells inhibited xenograft tumor aggressiveness. Sections of the xenograft tumor generated by A549-scramble, A549-cramble-NNK, A549-ShCD36, or A549-ShCD36-NNK cells were stained with H&E and examined. Note the poorly differentiated and more aggressive cells in A549-scramble-NNK tumors (Spindle cells (red arrows), cells with high nuclear-cytoplasm ratio (green arrows), mitotic cells (black arrows)) were indicated. Bar: 200 and 40 μm, respectively.(C) CD36 IHC staining in the xenograft tumors. Immunohistochemical analysis of tumors with antibodies against CD36 was performed. IH-scores for CD36 were calculated for tumors, and the results represent the mean ± SD of four individual tumors per group (∗p < 0.05). Bar: 200 μm.(D) CD36 knockdown inhibited Src/ERK1/2/Akt activation in xenograft tumor tissues. Five of each group of xenograft tumor tissue proteins was pooled together and the indicated protein expression and activity in the xenografts were detected.(E) Detection of lung metastasis of tail-vein injected LUAD cells. Lungs of nude mice 12 weeks after tail-vein injection of A549-scramble, A549-scramble-NNK, A549-ShCD36, or A549-ShCD36-NNK cells were collected. Gross appearance and total number of metastatic nodules in lungs of nude mice were analyzed. Arrows indicated nodules formed on the lungs. Nodule numbers of individual mouse for each group were counted and summarized by the column figure. Data were mean ± SD (∗p < 0.05 and ∗∗p < 0.01 vs. Scramble; @@p < 0.01 vs. Scramble-NNK; n = 4).(F) Pathologic analyses of the lungs after tail-vein injection of LUAD cells. Lung tissue sections from mice of A549-scramble, A549-scramble-NNK, A549-ShCD36, or A549-ShCD36-NNK group were stained with H&E and examined. Bar: 600 and 200 μm, respectively.(G) IHC staining of the lungs after tail-vein injection of LUAD cells. Lung tissue sections from mice of A549-scramble, A549-ShCD36, A549-scramble-NNK, or A549-ShCD36-NNK group were stained with CD36 antibody and examined. Bar: 200 and 50 μm, respectively.
Fig 5: CD36 interacted with both α7nAChR and Src to mediate NNK-induced signaling during LUAD carcinogenesis(A) CD36 inhibitor SSO blocked NNK- and PA-induced activation of Src/Akt/ERK1/2. NCI-H23 cells were untreated or treated with 10 μM NNK, or cells were pretreated with 200 μM SSO (a fatty acid analog as CD36 blocker) for 30 min, which was followed by 10 μM NNK or 500 μM PA treatment for 0.5/12 h. Untreated cells were set up as controls. Proteins expression and activity were determined by western blot.(B–E) Examination of the interaction among α7nAChR, CD36, and Src by immunoprecipitation. Briefly, NCI-H23 cells were treated with 10 μM NNK or 500 μM PA for 0.5 h. Untreated cells were set up as controls. Total cell lysis (input) was detected with indicated antibodies. CD36 immunoprecipitates (IP by CD36 antibody) were examined with (B) α7nAChR and (C) Src antibodies, respectively; Src immunoprecipitates (IP by Src antibody) were examined with (D) α7nAChR and (E) CD36 antibodies, respectively.(F–H) Examination of the colocalization among α7nAChR, CD36, and Src by immunostaining. Briefly, NCI-H23 cells were untreated or treated with 10 μM NNK for 0.5 or 12 h. Untreated cells were set up as controls. The fixed cells were double stained for (F) CD36 (red) and α7nAChR (green); (G) Src (red) and CD36 (green); and (H) Src (red) and α7nAChR (green), respectively. Bar, 10 μm. The images were representative of three experiments.
Supplier Page from OriGene Technologies for CD36 Human shRNA Plasmid Kit (Locus ID 948)